Infigratinib, which has shown strong inhibitory effects and promising application prospects in urothelial carcinoma with FGFR3 gene mutation and locally advanced or metastatic gastric cancer with FGFR2 gene amplification, was approved by the FDA for advanced cholangiocarcinoma with FGFR2 fusion and rearrangement in May 2021 and is currently in clinical trials for first-line treatment of cholangiocarcinoma [20, 46–48]. This evidence concerns the gene FGFR3 and urothelial carcinoma.